274 related articles for article (PubMed ID: 18818197)
21. Structural biology and biochemistry of cytochrome P450 systems in Mycobacterium tuberculosis.
McLean KJ; Munro AW
Drug Metab Rev; 2008; 40(3):427-46. PubMed ID: 18642141
[TBL] [Abstract][Full Text] [Related]
22. Expression, purification and spectroscopic characterization of the cytochrome P450 CYP121 from Mycobacterium tuberculosis.
McLean KJ; Cheesman MR; Rivers SL; Richmond A; Leys D; Chapman SK; Reid GA; Price NC; Kelly SM; Clarkson J; Smith WE; Munro AW
J Inorg Biochem; 2002 Sep; 91(4):527-41. PubMed ID: 12237220
[TBL] [Abstract][Full Text] [Related]
23. Structure-Function Analysis of the Essential
Padayachee T; Lamb DC; Nelson DR; Syed K
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732102
[TBL] [Abstract][Full Text] [Related]
24. Phenylalanine 393 exerts thermodynamic control over the heme of flavocytochrome P450 BM3.
Ost TW; Miles CS; Munro AW; Murdoch J; Reid GA; Chapman SK
Biochemistry; 2001 Nov; 40(45):13421-9. PubMed ID: 11695888
[TBL] [Abstract][Full Text] [Related]
25. Glycosylated Flavonoid Compounds as Potent CYP121 Inhibitors of
Bajrai LH; Khateb AM; Alawi MM; Felemban HR; Sindi AA; Dwivedi VD; Azhar EI
Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291570
[TBL] [Abstract][Full Text] [Related]
26. QM/MM study of the C-C coupling reaction mechanism of CYP121, an essential cytochrome p450 of Mycobacterium tuberculosis.
Dumas VG; Defelipe LA; Petruk AA; Turjanski AG; Marti MA
Proteins; 2014 Jun; 82(6):1004-21. PubMed ID: 24356896
[TBL] [Abstract][Full Text] [Related]
27. Atomic structure of Mycobacterium tuberculosis CYP121 to 1.06 A reveals novel features of cytochrome P450.
Leys D; Mowat CG; McLean KJ; Richmond A; Chapman SK; Walkinshaw MD; Munro AW
J Biol Chem; 2003 Feb; 278(7):5141-7. PubMed ID: 12435731
[TBL] [Abstract][Full Text] [Related]
28. Nanoelectrospray ionization mass spectrometric study of Mycobacterium tuberculosis CYP121-ligand interactions.
Duffell KM; Hudson SA; McLean KJ; Munro AW; Abell C; Matak-Vinković D
Anal Chem; 2013 Jun; 85(12):5707-14. PubMed ID: 23675886
[TBL] [Abstract][Full Text] [Related]
29. Substrate Fragmentation for the Design of M. tuberculosis CYP121 Inhibitors.
Kavanagh ME; Gray JL; Gilbert SH; Coyne AG; McLean KJ; Davis HJ; Munro AW; Abell C
ChemMedChem; 2016 Sep; 11(17):1924-35. PubMed ID: 27432475
[TBL] [Abstract][Full Text] [Related]
30. A comparison of steroid and lipid binding cytochrome P450s from Mycobacterium marinum and Mycobacterium tuberculosis.
Child SA; Ghith A; Bruning JB; Bell SG
J Inorg Biochem; 2020 Aug; 209():111116. PubMed ID: 32473484
[TBL] [Abstract][Full Text] [Related]
31. Biophysical Screening of a Focused Library for the Discovery of CYP121 Inhibitors as Novel Antimycobacterials.
Brengel C; Thomann A; Schifrin A; Allegretta G; Kamal AAM; Haupenthal J; Schnorr I; Cho SH; Franzblau SG; Empting M; Eberhard J; Hartmann RW
ChemMedChem; 2017 Oct; 12(19):1616-1626. PubMed ID: 28815923
[TBL] [Abstract][Full Text] [Related]
32. Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?
Ortega Ugalde S; Boot M; Commandeur JNM; Jennings P; Bitter W; Vos JC
Appl Microbiol Biotechnol; 2019 May; 103(9):3597-3614. PubMed ID: 30810776
[TBL] [Abstract][Full Text] [Related]
33. Acetylene containing cyclo(L-Tyr-L-Tyr)-analogs as mechanism-based inhibitors of CYP121A1 from Mycobacterium tuberculosis.
Ortega Ugalde S; Wallraven K; Speer A; Bitter W; Grossmann TN; Commandeur JNM
Biochem Pharmacol; 2020 Jul; 177():113938. PubMed ID: 32224137
[TBL] [Abstract][Full Text] [Related]
34. Crystallization and preliminary crystallographic analysis of a novel cytochrome P450 from Mycobacterium tuberculosis.
Mowat CG; Leys D; McLean KJ; Rivers SL; Richmond A; Munro AW; Ortiz Lombardia M; Alzari PM; Reid GA; Chapman SK; Walkinshaw MD
Acta Crystallogr D Biol Crystallogr; 2002 Apr; 58(Pt 4):704-5. PubMed ID: 11914502
[TBL] [Abstract][Full Text] [Related]
35. Crystallographic insights into a cobalt (III) sepulchrate based alternative cofactor system of P450 BM3 monooxygenase.
Panneerselvam S; Shehzad A; Mueller-Dieckmann J; Wilmanns M; Bocola M; Davari MD; Schwaneberg U
Biochim Biophys Acta Proteins Proteom; 2018 Jan; 1866(1):134-140. PubMed ID: 28739446
[TBL] [Abstract][Full Text] [Related]
36. [Research progresses of Mycobacterium tuberculosis cytochrome P450s as a potential drug target].
Lu Y; Qiao F; You XF; Yang XY
Yao Xue Xue Bao; 2014 Apr; 49(4):427-34. PubMed ID: 24974457
[TBL] [Abstract][Full Text] [Related]
37. 4-cyanopyridine, a versatile spectroscopic probe for cytochrome P450 BM3.
Ost TW; Clark JP; Anderson JL; Yellowlees LJ; Daff S; Chapman SK
J Biol Chem; 2004 Nov; 279(47):48876-82. PubMed ID: 15364917
[TBL] [Abstract][Full Text] [Related]
38. Phe393 mutants of cytochrome P450 BM3 with modified heme redox potentials have altered heme vinyl and propionate conformations.
Chen Z; Ost TW; Schelvis JP
Biochemistry; 2004 Feb; 43(7):1798-808. PubMed ID: 14967021
[TBL] [Abstract][Full Text] [Related]
39. Structure-Activity Relationships of
Rajput S; McLean KJ; Poddar H; Selvam IR; Nagalingam G; Triccas JA; Levy CW; Munro AW; Hutton CA
J Med Chem; 2019 Nov; 62(21):9792-9805. PubMed ID: 31618032
[TBL] [Abstract][Full Text] [Related]
40. Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors.
Kavanagh ME; Coyne AG; McLean KJ; James GG; Levy CW; Marino LB; de Carvalho LP; Chan DS; Hudson SA; Surade S; Leys D; Munro AW; Abell C
J Med Chem; 2016 Apr; 59(7):3272-302. PubMed ID: 27002486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
